Skip to content

Delivering on genetic medicines

Aera’s mission is to unlock the potential of genetic medicines by tacking the greatest unmet need in the field today – delivery. Aera has two proprietary delivery platforms – lipid nanoparticles (LNPs) and protein nanoparticles (PNPs) – that are being developed to enable next-generation genetic medicines across a range of therapeutic modalities and disease areas. These platforms have the potential to overcome the limitations of today’s delivery technologies and expand the application of genetic medicines.

Our Science

Creating a leading genetic medicines company

Leadership

Aera is led by a distinguished team of scientists and company builders.

Are you passionate about science and making an impact? Join us.

View Careers

Top